REDWOOD CITY, CA -- (MARKET WIRE) -- 01/11/2006 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced positive results from the Phase 1 portion of a Phase 1/2 dose-escalation study of glufosfamide in combination with gemcitabine for the treatment of advanced solid tumors and pancreatic cancer. Glufosfamide was well-tolerated and warrants further investigation at the maximum tolerated dose (MTD) in combination with gemcitabine.
